ClinicalTrials.Veeva

Menu

Exploration of High Frequency Otoacoustic Emissions and Developmental Language Disorders (OTOEMHF)

U

University Hospital, Clermont-Ferrand

Status

Not yet enrolling

Conditions

Language Development Disorders

Treatments

Diagnostic Test: Audiometry
Diagnostic Test: Otoscopy
Diagnostic Test: acoustic otoemisions
Diagnostic Test: Tympanometry

Study type

Interventional

Funder types

Other

Identifiers

NCT05624983
RBHP 2022 SARRET

Details and patient eligibility

About

Among the objective non-invasive audiological explorations the distorsion products of otoacoustic emissions (DPOAE) allow to quickly assess the function of the cochlear outer hair cells (without the active participation of the subject). This technique is used in newborn screening. While humans are able to perceive sounds in a frequency range of 20Hz to 20kHz, routine clinical audiological assessment is only concerned with frequencies between 1-4kHz.

This obscures the importance of high frequencies (HF) which can be easily assessed by DPOAEs. In young children, the perception of these high frequencies could also play an important role in language acquisition.

The main objective of this study is to evaluate the relationship between subtle high-frequency hearing impairment, as assessed by the DPOAE (non-invasive, rapid and simple audiological test), and language delay or difficulties in a pre-, peri- and school-age pediatric population.

Enrollment

138 estimated patients

Sex

All

Ages

2 to 17 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for case (children with language disorder):

  • Normal hearing (after an audiometry test, even if an ENT consultation has been carried out beforehand and if the doctor has not found any hearing problem, as defined in the NF EN ISO 70292017-04 standard, and according to an average hearing loss calculated according to the BIAP <20dB HL)
  • Free and informed consent of the parental authority and the patient
  • Affiliated to the social security system
  • Presenting a developmental language acquisition disorder (score according to the EVALO / EVALEO test)
  • For children between 15 and 17 years of age, completion of the EVALEO test before their 16th birthday

Inclusion Criteria for control (children without language disorder) :

  • Normal hearing (after an audiometry test, even if an ENT consultation has been performed beforehand and if the doctor has not found any hearing problem, as defined in the NF EN ISO 70292017-04 standard, and according to an average hearing loss calculated according to the BIAP <20dB HL)
  • Free and informed consent of the parental authority and the patient
  • Enrolled in the social security system

Exclusion Criteria:

  • Hearing disorder identified during the inclusion visit (presence of cerumen or foreign body in the earwax plug or foreign body in the external auditory canal, tympanometry suggesting a middle ear disorder, audiometry with thresholds outside the normal thresholds outside the normal range (0-20dB HL), absence of responses in (0-20dB HL), absence of responses in acoustic otoemissions or acoustic distortion products) on conversational frequencies between 500Hz and 4kHz.
  • Declaration by the parents of an ENT follow-up for a hearing disorder and/or a speech therapy for a language disorder
  • Refusal of participation evoked by the subject

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

138 participants in 2 patient groups

Case group (children with language disorder)
Experimental group
Description:
Hearing diagnostic test
Treatment:
Diagnostic Test: Audiometry
Diagnostic Test: Tympanometry
Diagnostic Test: Otoscopy
Diagnostic Test: acoustic otoemisions
controle group (children without language disorder)
Other group
Description:
Hearing diagnostic test
Treatment:
Diagnostic Test: Audiometry
Diagnostic Test: Tympanometry
Diagnostic Test: Otoscopy
Diagnostic Test: acoustic otoemisions

Trial contacts and locations

1

Loading...

Central trial contact

Lise Laclautre

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems